These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12511855)

  • 1. Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis.
    Dandekar PK; Nicolau DP
    Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S10-6. PubMed ID: 12511855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute bacterial rhinosinusitis in pediatric medicine: current issues in diagnosis and management.
    Anon JB
    Paediatr Drugs; 2003; 5 Suppl 1():25-33. PubMed ID: 14632103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing clinical outcomes by the use of pharmokinetic and pharmacodynamic principles.
    Quintiliani R
    J Med Liban; 2000; 48(4):182-5. PubMed ID: 11214187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis.
    Hadley JA; Pfaller MA
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):47S-54S. PubMed ID: 17292580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloperoxidase in nasal secretion as a cell-activation marker in acute sinusitis.
    Haxel BR; Woywode C; Mewes T; Mann WJ
    Am J Rhinol; 2004; 18(2):93-8. PubMed ID: 15152874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral β-Lactam Antibiotics for Pediatric Otitis Media, Rhinosinusitis, and Pneumonia.
    Molloy L; Barron S; Khan N; Abrass E; Ang J; Abdel-Haq N
    J Pediatr Health Care; 2020; 34(3):291-300. PubMed ID: 32334748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
    Poachanukoon O; Kitcharoensakkul M
    Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral cephalosporins in the treatment of acute otitis media in children.
    Brook I
    Int J Antimicrob Agents; 2004 Jul; 24(1):18-23. PubMed ID: 15225855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sinus fluid penetration of oral clarithromycin and azithromycin in patients with acute rhinosinusitis.
    Margaritis VK; Ismailos GS; Naxakis SS; Mastronikolis NS; Goumas PD
    Am J Rhinol; 2007; 21(5):574-8. PubMed ID: 17999793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-a-day cephalosporins: reality or myth?
    Scaglione F; Dugnani S; Fraschini F
    J Chemother; 1995 May; 7 Suppl 1():13-5. PubMed ID: 8618107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute bacterial rhinosinusitis: a review of U.S. treatment guidelines.
    Marple BF; Brunton S; Ferguson BJ
    Otolaryngol Head Neck Surg; 2006 Sep; 135(3):341-8. PubMed ID: 16949962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era.
    Owens RC; Ambrose PG
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):77S-83S. PubMed ID: 17292579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management update of acute bacterial rhinosinusitis and the use of cefdinir.
    Gwaltney JM
    Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S24-9. PubMed ID: 12511857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatment of rhinosinusitis in children.
    Novembre E; Mori F; Pucci N; Bernardini R; Vierucci A; de Martino M
    Pediatr Allergy Immunol; 2007 Nov; 18 Suppl 18():56-61. PubMed ID: 17767611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of cefovecin in dogs.
    Stegemann MR; Sherington J; Blanchflower S
    J Vet Pharmacol Ther; 2006 Dec; 29(6):501-11. PubMed ID: 17083454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of acute bacterial rhinosinusitis: current issues and future perspectives.
    Desrosiers M; Klossek JM; Benninger M
    Int J Clin Pract; 2006 Feb; 60(2):190-200. PubMed ID: 16451293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
    Preston SL
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of meropenem.
    Nicolau DP
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential new avenues of treatment for chronic rhinosinusitis: an anti-inflammatory approach.
    Statham MM; Seiden A
    Otolaryngol Clin North Am; 2005 Dec; 38(6):1351-65, xi. PubMed ID: 16326190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.